Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Narrative) (Details)

v3.22.0.1
Stockholders' Equity (Narrative) (Details)
 1 Months Ended 6 Months Ended 8 Months Ended
Oct. 31, 2021
$ / shares
Oct. 29, 2019
$ / shares
shares
Jun. 26, 2018
shares
Feb. 23, 2017
USD ($)
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Sep. 30, 2021
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
shares
Jun. 30, 2020
USD ($)
shares
Nov. 01, 2021
$ / shares
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Jun. 20, 2018
shares
Stockholders' Equity [Line Items]                        
Exercise of warrants (in shares)                 29,100,000      
Proceeds from exercise of warrants | $                 $ 6,400,000      
Shares of common stock issued for the cashless exercise of Warrants                 5,900,000      
Cashless exercise of warrants reducing balance owed for notes payable - warrant exchange | $                 $ 1,300,000      
Costs related to the warrant exchange offset against additional paid-in capital | $                 313,000      
Common stock, par value (in dollars per share) | $ / shares         $ 0.001   $ 0.001       $ 0.001  
Preferred Stock, shares authorized       1,000,000 1,000,000   1,000,000          
Cost related to issuance of shares | $             $ 0 $ 4,642,000        
Common stock, shares authorized (in shares)         275,000,000   275,000,000       275,000,000  
Proceeds from Warrant Exercises | $                 $ 6,400,000      
Stock Issued During Period, Shares, Warrants Exercised                 29,100,000      
Exercise of stock options (in shares)           84,500            
Proceeds from the exercise of stock options | $             $ 77,000 $ 28,000        
Weighted average risk-free interest rate                        
Stockholders' Equity [Line Items]                        
Fair value of the Warrant assumptions         0.23   0.23          
Dividend yield                        
Stockholders' Equity [Line Items]                        
Fair value of the Warrant assumptions         0   0          
Volatility                        
Stockholders' Equity [Line Items]                        
Fair value of the Warrant assumptions         136.9   136.9          
Expected term (in years)                        
Stockholders' Equity [Line Items]                        
Fair value of the Warrant assumptions         4.95   4.95          
College Station Investors LLC And Bryan Capital [Member]                        
Stockholders' Equity [Line Items]                        
Warrants to purchase shares of Common Stock                   1,289,581    
Warrants, exercise price per share | $ / shares                   $ 1.33    
Series A Common Stock Purchase Warrants [Member]                        
Stockholders' Equity [Line Items]                        
Warrants outstanding         0   0          
Number of shares issued   25,000,000                    
Warrants, exercise price per share | $ / shares   $ 0.22                    
Term of the warrants   2 years                    
Series B Common Stock Purchase Warrants [Member]                        
Stockholders' Equity [Line Items]                        
Warrants outstanding               0        
Number of shares issued   25,000,000                    
Warrants, exercise price per share | $ / shares   $ 0.22                    
Term of the warrants   7 years                    
Series A Preferred Stock [Member]                        
Stockholders' Equity [Line Items]                        
Number of shares designated                       6,300
Preferred stock, par value (in dollars per share) | $ / shares         $ 0.001   $ 0.001          
Number of common stock issued upon conversion     8,357,997                  
Preferred stock, shares outstanding (in shares)         0   0          
Series B Preferred Stock [Member]                        
Stockholders' Equity [Line Items]                        
Number of common stock issued upon conversion     28,935,000                  
Preferred stock, shares outstanding (in shares)         0   0          
Series C Preferred Stock [Member]                        
Stockholders' Equity [Line Items]                        
Number of common stock issued upon conversion   22,550,000                    
Preferred stock, shares outstanding (in shares)         0   0          
iBio CMO Preferred Tracking Stock [Member]                        
Stockholders' Equity [Line Items]                        
Preferred Stock, Dividend Rate, Percentage       2.00%                
Preferred Stock, Dividends Per Share, Declared | $ / shares $ 0                      
Dividends Payable | $         $ 0   $ 0       $ 1,131,000  
Preferred stock, shares outstanding (in shares)                   0    
Restricted Stock Units [Member]                        
Stockholders' Equity [Line Items]                        
Shares vested         103,003              
Omnibus Incentive (the 2020) Plan [Member]                        
Stockholders' Equity [Line Items]                        
Shares available for grant under the plan         32,000,000   32,000,000          
Underwritten Public Offering [Member]                        
Stockholders' Equity [Line Items]                        
Number of shares issued     6,300                  
Underwritten Public Offering [Member] | Series B Preferred Stock [Member]                        
Stockholders' Equity [Line Items]                        
Number of shares issued     5,785                  
Underwritten Public Offering [Member] | Series C Preferred Stock [Member]                        
Stockholders' Equity [Line Items]                        
Number of shares issued   4,510                    
Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | Bioprocessing (iBio CDMO) [Member]                        
Stockholders' Equity [Line Items]                        
Stock Issued During Period, Shares, Acquisitions       1                
Number of LLC interest units exchanged for each share of preferred tracking stock       29,990,000                
Proceeds from sale of shares, net of issuance cost | $       $ 13,000,000                
Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]                        
Stockholders' Equity [Line Items]                        
Noncontrolling Interest, Ownership Percentage by Parent       99.99%                
Exchange Agreement [Member] | Eastern Affiliate [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]                        
Stockholders' Equity [Line Items]                        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners       0.01%